Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and
middle‐aged women. It usually lasts for several years (> 1 year in 25–75% of patients) and …

Novel therapies such as type 2 targeting biologics are emerging treatment options for
patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely …

Background Autoimmune chronic spontaneous urticaria (aiCSU) is an important subtype of
chronic spontaneous urticaria (CSU) in which functional IgG autoantibodies to IgE or its high …

The current therapeutic algorithm for chronic spontaneous urticaria (CSU), endorsed by the
international guideline, entails treatment escalation from second‐generation H1 …

Guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend the use of
the IgE-targeted biologic omalizumab in patients with antihistamine-refractory disease. The …

This is Part 1 of an updated follow-up review of a World Allergy Organization (WAO) position
paper published in 2012 on the diagnosis and treatment of urticaria and angioedema. Since …

Objective Immunoglobulin E (IgE) and its receptor, FcɛRI, importantly contribute to the
pathophysiology of chronic spontaneous urticaria (CSU). Recent findings point to a possible …

Chronic urticaria (CU) is a common skin condition characterized by the recurrence of
wheals, with or without angioedema, which lasts for at least 6 weeks. Owing to its pruritus …

Immunoglobulin E (IgE) plays an essential role in many allergic diseases. This review
highlights the role of IgE in atopic dermatitis (AD), a common, chronic, and complex skin …

Chronic spontaneous urticaria (CSU) is a frequent and often severely disabling disease. A
large number of studies were performed during the last 2 decades to clarify its pathogenesis …